G. Draffan Gavrish Choi A. De Groote Butler G. Franzblau

99 MONDAY SCIENTIFIC SESSIONS Final Program F-826 Identification and Analysis of Hepatitis C virus NS3 Helicase Inhibitors Using a Nucleic Acid Binding Assay S. Mukherjee, A. M. Hanson, J. Ndjomou, D. Bartczak, L. A. Arnold, and D. N. Frick; Univ. of Wisconsin, Milwaukee, WI. F-827 Identification of Novel Small Molecule Inhibitors against the NS34A Serine Protease of Hepatitis C Virus by High-Through- put Screening H. Lee, T. Zhu, Y. Zhang, K. Patel, L. Truong, A. Sarkar, H. Jeong, M. E. Johnson; Univ. of Illinois, Chicago, IL. F-828 Discovery of a New Series of Pan-Genotypic NS5b Inhibitors for Hepatitis C: The Indazole Amide Class of Site IV Polymerase Antivirals

A. G. Draffan

1 , S. Bond 1 , J. Cianci 1 , B. Frey 1 , M. Frazetto 1 , R. Halim 1 , S. Hamilton 1 , M. Harding 1 , R. Hufton 1 , S. Jahangiri 1 , T. Jeynes 1 , M. Lilly 1 , B. Lin 1 , A. Luttick 1 , C. Morton 1,2 , T. Nero 2 , B. Pool 1 , M. Parker 2 , K. Porter 1 , M. Pryor 1 , J. Thomas 1 , S. Tucker 1 , J. Wielens 2 , V. Wirth 1 ; 1 Biota Scien- tific Management, Melbourne, Australia, 2 St. Vincent’s Inst. of Med. Res., Melbourne, Australia. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 098 F Poster Session New Approaches in Mycobacterial Therapy Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-829 Novo23: A Novel Antibiotic With Specific Activity against Mycobacterium Tuberculosis

E. Gavrish

1 , A. Peoples 2 , A. Spoering 2 , A. Bissell 1 , W. Millett 2 , L. Ling 2 , D. Hughes 2 , K. Lewis 1 ; 1 Northeastern Univ., Boston, MA, 2 NovoBiotic Pharmaceuticals, LLC, Cambridge, MA. F-830 Enhanced Activity of 13C-Isoniazid Using Magnetic Isotope Effect

S. Choi

1 , R. Gupta 2 , L. Silks 3 , W. Bishai 2 , G. Timmins 1 ; 1 Univ. of New Mexico, Albuquerque, NM, 2 Johns Hopkins Hosp., Baltimore, 3 Los Alamos Natl. Lab., Los Alamos, NM. F-831 The Search for New Antimicrobial Agents against Mycobacte- rium abscessus,

M. A. De Groote

1 , S. Cho 2 , L. L. Klein 2 , S. G. Franzblau 2; 1 Colorado State Univ., Fort Collins, CO, 2 Univ. of Illiniois at Chicago, Chicago, IL. F-832 Anti-Bacterial Activity and Postantibiotic Effect of Novel Spectinamide Analogs against Mycobacterium Tuberculosis M. M. Butler 1 , D. F. Bruhn 2 , H. I. M. Boshoff 3 , J. Liu 2 , T. L. Bowlin 1 , R. E. Lee 2 ; 1 Microbiotix, Inc., Worcester, MA, 2 St. Jude Children’s Res. Hosp., Memphis, TN, 3 NIAID, Bethesda, MD. F-833 Antimicrobial Activity of Five Essential Oils and Their Compounds against Mycobacterium Tuberculosis S. Andrade Ochoa, K. F. Chacon Vargas, L. R. Hernández Ochoa, L. M. Rodriguez Valdez, G. V. Nevarez Moorillón, B. R. Rivera Chavira; Univ. Autonoma de Chihuahua, Chihuahua, Mexico. F-834 Anti-Tuberculosis In Vitro Activity of the Nitroimidazole TBA-354 S. Franzblau 1 , S. Cho 1 , Y. Wang 1 , Y. Lu 2 , B. Wang 2 , J. Xu 2 , K. Mdluli 3 , A. M. Upton 3 , Z. Ma 3 ; 1 Inst. for Tuberculosis Res., Univ. of Illinois, Chicago, IL, 2 Beijing Tuberculosis and Thoracic Tumor Res. Inst., Beijing, China, 3 Global Alliance for TB Drug Dev., New York, NY. F-835 In Vivo Anti-Tuberculosis Activity of the Nitroimidazole TBA-354 against Acute and Chronic Murine Tuberculosis

S. G. Franzblau

1 , Y. Wang 1 , A. M. Upton 2 , K. Mdluli 2 , Z. Ma 2 ; 1 Inst. for Tuberculosis Res., Univ. of Illinois, Chicago, IL, 2 Global Alliance for TB Drug Dev., New York, NY. F-836 Activity of the Nitroimidazole TBA-354 Alone and in a Novel Drug Regimen in Two Murine Models of Tuberculosis

E. Nuermberger